{"schema_version":"secwatch.filing_event.v1","accession":"0001396814-24-000044","form_type":"8-K","ticker":"PCRX","cik":"0001396814","company_name":"Pacira BioSciences, Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.231201+00:00","generated_at":"2026-06-02T17:17:22.731398+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Pacira Q1 net income $9.0M ($0.19 EPS); announces $150M share repurchase","bullets":["GAAP net income $9.0M ($0.19/sh) vs net loss $19.5M ($0.43 loss) YoY.","Total revenue $167.1M, up from $160.3M YoY; EXPAREL net sales $132.4M.","Adjusted EBITDA $44.6M vs $41.9M YoY; cash flow from ops $49.1M.","Board authorizes $150M share repurchase program through Dec 2026.","FY2024 guidance reaffirmed: revenue $680M-$705M, non-GAAP gross margin 74%-76%."],"urls":{"canonical":"https://secwatch.observer/filing/0001396814-24-000044","json":"https://secwatch.observer/filing/0001396814-24-000044.json","markdown":"https://secwatch.observer/filing/0001396814-24-000044.md","text":"https://secwatch.observer/filing/0001396814-24-000044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1396814/000139681424000044/0001396814-24-000044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1396814/000139681424000044/pcrx-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T17:17:22.731398+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"229c82688eb70de375dc4291fe2070d8f45fdd60","claim":"Pacira BioSciences, Inc. reported first quarter ended March 31, 2024 results: revenue $167.1 million, net income $9.0 million, EPS $0.19 per share (basic and diluted).","evidence_excerpt":"First Quarter 2024 Financial Highlights • Total revenues of $167.1 million • Net product sales of $132.4 million for EXPAREL, $25.8 million for ZILRETTA, and $5.0 million for iovera° • Net income of $9.0 million, or $0.19 per share (basic and diluted)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1396814/000139681424000044/0001396814-24-000044-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$167.1 million"},{"label":"Net income","value":"$9.0 million"},{"label":"EPS","value":"$0.19 per share (basic and diluted)"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}